TY - JOUR
T1 - An international multidisciplinary consensus on pediatric metabolic dysfunction-associated fatty liver disease
AU - Zhang, Le
AU - El-Shabrawi, Mortada
AU - Baur, Louise A.
AU - Byrne, Christopher D.
AU - Targher, Giovanni
AU - Kehar, Mohit
AU - Porta, Gilda
AU - Lee, Way Seah
AU - Lefere, Sander
AU - Turan, Serap
AU - Alisi, Anna
AU - Weiss, Ram
AU - Faienza, Maria Felicia
AU - Ashraf, Ambika
AU - Sundaram, Shikha S.
AU - Srivastava, Anshu
AU - De Bruyne, Ruth
AU - Kang, Yunkoo
AU - Bacopoulou, Flora
AU - Zhou, Yong Hai
AU - Darma, Andy
AU - Lupsor-Platon, Monica
AU - Hamaguchi, Masahide
AU - Misra, Anoop
AU - Méndez-Sánchez, Nahum
AU - Ng, Nicholas Beng Hui
AU - Marcus, Claude
AU - Staiano, Amanda E.
AU - Waheed, Nadia
AU - Alqahtani, Saleh A.
AU - Giannini, Cosimo
AU - Ocama, Ponsiano
AU - Nguyen, Mindie H.
AU - Arias-Loste, Maria Teresa
AU - Ahmed, Mohamed Rabea
AU - Sebastiani, Giada
AU - Poovorawan, Yong
AU - Al Mahtab, Mamun
AU - Pericàs, Juan M.
AU - Reverbel da Silveira, Themis
AU - Hegyi, Peter
AU - Azaz, Amer
AU - Isa, Hasan M.
AU - Lertudomphonwanit, Chatmanee
AU - Farrag, Mona Issa
AU - Nugud, Ahmed Abd Alwahab
AU - Du, Hong Wei
AU - Qi, Ke Min
AU - Mouane, Nezha
AU - Cheng, Xin Ran
AU - Al Lawati, Tawfiq
AU - Fagundes, Eleonora D.T.
AU - Ghazinyan, Hasmik
AU - Hadjipanayis, Adamos
AU - Fan, Jian Gao
AU - Gimiga, Nicoleta
AU - Kamal, Naglaa M.
AU - Ștefănescu, Gabriela
AU - Hong, Li
AU - Diaconescu, Smaranda
AU - Li, Ming
AU - George, Jacob
AU - Zheng, Ming Hua
N1 - Publisher Copyright:
© 2024 Elsevier Inc.
PY - 2024/7/12
Y1 - 2024/7/12
N2 - Background: Non-alcoholic fatty liver disease (NAFLD) is highly prevalent in children and adolescents, particularly those with obesity. NAFLD is considered a hepatic manifestation of the metabolic syndrome due to its close associations with abdominal obesity, insulin resistance, and atherogenic dyslipidemia. Experts have proposed an alternative terminology, metabolic dysfunction-associated fatty liver disease (MAFLD), to better reflect its pathophysiology. This study aimed to develop consensus statements and recommendations for pediatric MAFLD through collaboration among international experts. Methods: A group of 65 experts from 35 countries and six continents, including pediatricians, hepatologists, and endocrinologists, participated in a consensus development process. The process encompassed various aspects of pediatric MAFLD, including epidemiology, mechanisms, screening, and management. Findings: In round 1, we received 65 surveys from 35 countries and analyzed these results, which informed us that 73.3% of respondents agreed with 20 draft statements while 23.8% agreed somewhat. The mean percentage of agreement or somewhat agreement increased to 80.85% and 15.75%, respectively, in round 2. The final statements covered a wide range of topics related to epidemiology, pathophysiology, and strategies for screening and managing pediatric MAFLD. Conclusions: The consensus statements and recommendations developed by an international expert panel serve to optimize clinical outcomes and improve the quality of life for children and adolescents with MAFLD. These findings emphasize the need for standardized approaches in diagnosing and treating pediatric MAFLD. Funding: This work was funded by the National Natural Science Foundation of China (82070588, 82370577), the National Key R&D Program of China (2023YFA1800801), National High Level Hospital Clinical Research Funding (2022-PUMCH-C-014), the Wuxi Taihu Talent Plan (DJTD202106), and the Medical Key Discipline Program of Wuxi Health Commission (ZDXK2021007).
AB - Background: Non-alcoholic fatty liver disease (NAFLD) is highly prevalent in children and adolescents, particularly those with obesity. NAFLD is considered a hepatic manifestation of the metabolic syndrome due to its close associations with abdominal obesity, insulin resistance, and atherogenic dyslipidemia. Experts have proposed an alternative terminology, metabolic dysfunction-associated fatty liver disease (MAFLD), to better reflect its pathophysiology. This study aimed to develop consensus statements and recommendations for pediatric MAFLD through collaboration among international experts. Methods: A group of 65 experts from 35 countries and six continents, including pediatricians, hepatologists, and endocrinologists, participated in a consensus development process. The process encompassed various aspects of pediatric MAFLD, including epidemiology, mechanisms, screening, and management. Findings: In round 1, we received 65 surveys from 35 countries and analyzed these results, which informed us that 73.3% of respondents agreed with 20 draft statements while 23.8% agreed somewhat. The mean percentage of agreement or somewhat agreement increased to 80.85% and 15.75%, respectively, in round 2. The final statements covered a wide range of topics related to epidemiology, pathophysiology, and strategies for screening and managing pediatric MAFLD. Conclusions: The consensus statements and recommendations developed by an international expert panel serve to optimize clinical outcomes and improve the quality of life for children and adolescents with MAFLD. These findings emphasize the need for standardized approaches in diagnosing and treating pediatric MAFLD. Funding: This work was funded by the National Natural Science Foundation of China (82070588, 82370577), the National Key R&D Program of China (2023YFA1800801), National High Level Hospital Clinical Research Funding (2022-PUMCH-C-014), the Wuxi Taihu Talent Plan (DJTD202106), and the Medical Key Discipline Program of Wuxi Health Commission (ZDXK2021007).
KW - MAFLD
KW - MASLD
KW - Translation to population health
KW - adolescents
KW - children
KW - consensus
KW - metabolic dysfunction-associated fatty liver disease
KW - non-alcoholic fatty liver disease
UR - https://www.scopus.com/pages/publications/85192309800
UR - https://www.scopus.com/pages/publications/85192309800#tab=citedBy
U2 - 10.1016/j.medj.2024.03.017
DO - 10.1016/j.medj.2024.03.017
M3 - Article
C2 - 38677287
AN - SCOPUS:85192309800
SN - 2666-6359
VL - 5
SP - 797-815.e2
JO - Med
JF - Med
IS - 7
ER -